Recent advances in oral anticoagulation for atrial fibrillation

Therapeutic Advances in Cardiovascular Disease

Volumn 4, Issue 6, 2010, Pages 395-407

  Singh, Mukesh ^a   Adigopula, Sasikanth ^a   Patel, Pawan ^a   Kiran, Kranti ^a   Khosla, Sandeep ^a  

^a MOUNT SINAI HOSPITAL   (United States)

Author keywords

Atrial fibrillation; New oral anticoagulants; Oral factor Xa inhibitors; Oral thrombin inhibitors; Stroke prevention

Indexed keywords

813893; ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; AVE 3247; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A INHIBITOR; DABIGATRAN; DU 176B; EMD 503982; HEPARIN; KETOCONAZOLE; KFA 1982; LOW MOLECULAR WEIGHT HEPARIN; MACROLIDE; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; QUINIDINE; RIVAROXABAN; THROMBIN; THROMBIN INHIBITOR; TTP 889; UNCLASSIFIED DRUG; VERAPAMIL; WARFARIN; XIMELAGATRAN; YM 150;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPEPSIA; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; STROKE; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PRACTICE GUIDELINES AS TOPIC; THROMBOEMBOLISM; VITAMIN K;

EID: 78649440378     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944710386844     Document Type: Review

References (92)

1. ACC/AHA/ESC (2006) Guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to revise the 2001 guidelines for the management of patients atrial fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114: 700-752.
2. Agnelli, G., Haas, S., Ginsberg, J.S., Krueger, K.A., Dmitrienko, A. and Brandt, J.T. ( 2007) A phase II study of the oral factor Xa inhibitor LY 517717 for the prevention of venous thromboembolism after hip or knee replacement. Thromb Haemost 5: 746-753.
3. Agnelli, G., Haas, S.K., Ginsberg, J.S., Krueger, K.A., Dmitrienko, A., Brandt, J.T. et al. (2005) A phase II study of the safety and efficacy of a novel oral FXa inhibitor (LY-517717) for the prevention of venous thromboembolism following TKR or THR [abstract]. Blood 106: 278.
4. Albers, G.W., Diener, H.C., Frison, L., Grind, M., Nevinson, M., Partridge, S. et al. (2005) SPORTIF Executive Steering Committee for the SPORTIF V Investigators: Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: A randomized trial. JAMA 293: 690-698.
5. Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A. and Hylek, E. ( 2004) The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(Suppl): 204S-233S.
6. Antithrombotic Therapy in Atrial Fibrillation Study Group ( 2006) The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: Warfarin compared with aspirin. Zhonghua Xin Xue Guan Bing Za Zhi 34: 295-298.
7. Atrial Fibrillation Investigators (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials [published erratum appears in Arch Intern Med 1994; 154: 2254]. Arch Intern Med 154: 1449-1457.
8. Bauer, K.A. ( 2006) New anticoagulants. Hematology ( Am Soc Hematol Educ Program): 450-456.
9. Bradley, B.C., Perdue, K.S., Tisdel, K.A. and Gilligan, D.M. ( 2000) Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center. Am J Cardiol 85: 568-572.
10. Bungard, T.J., Ghali, W.A., Teo, K.K., McAlister, F.A. and Tsuyuki, R.T. ( 2000) Why do patients with atrial fibrillation not receive warfarin ? Arch Intern Med 160: 41-46.
11. Carreiro, J. and Ansell, J. ( 2008) Apixaban, an oral direct factor Xa inhibitor: Awaiting the verdict. Expert Opin Investig Drugs 17: 1937-1945.
12. ClinicalTrials.gov: NCT00119457. A multi-center, placebo-controlled evaluation of the safety and efficacy of three weeks extended VTE prophylaxis with daily oral doses of TTP 889 after one week of standard prophylactic treatment following hip fracture surgery (FIXIT). Available at: www.clinicaltrials.gov.
13. ClinicalTrials.gov: NCT00412984. A phase 3, active (warfarin) controlled, randomized, double-blind, parallel arm study to evaluate efficacy and safety of apixaban in preventing stroke and systemic embolism in subjects with nonvalvular atrial fibrillation (ARISTOTLE). Available at: www.clinicaltrials.gov.
14. ClinicalTrials.gov: NCT00448214. Direct factor Xa inhibitor YM 150 for prevention of stroke in subjects with non-valvular atrial fibrillation: A double blind, parallel, dose-finding study in comparison with open label warfarin. Available at: www.clinicaltrials.gov.
15. ClinicalTrials.gov: NCT00494871. Evaluation of the efficacy and safety of rivaroxaban (BAY59-7939) for the prevention of stroke and non-central nervous system systemic embolism in subjects with nonvalvular atrial fibrillation. Available at: www.clinicaltrials.gov.
16. ClinicalTrials.gov: NCT00496769. Apixaban versus acetylsalicylic acid (ASA) to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment: A randomized double blind trial (AVERROES). Available at: www.clinicaltrials.gov.
17. ClinicalTrials.gov: NCT00621855. Randomized dabigatran etexilate dose finding study in patients with acute coronary syndromes post index event with additional risk factors for cardiovascular complications also receiving aspirin and clopidogrel: Multi-centre, prospective, placebo controlled, cohort dose escalation study (RE-DEEM). Available at: www.clinicaltrials.gov.
18. ClinicalTrials.gov: NCT00781391. A phase 3, randomized, double-blind, double-dummy, parallel group, multi-center, Multi-national study for evaluation of efficacy and safety of DU-176b versus warfarin in subjects with atrial fibrillation: Effective anticoagulation with factor Xa next generation in atrial fibrillation (ENGAGE-AF TIMI-48). Available at: www.clinicaltrials.gov.
19. ClinicalTrials.gov: NCT00808067. RELY-ABLE long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed the RE-LY trial and a cluster randomised trial to assess the effect of a knowledge translation intervention on patient outcomes. Available at: www.clinicaltrials.gov.
20. Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A. et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (12): 1139-1151.
21. Connolly, S.J., Laupacis, A., Gent, M., Roberts, R.S., Cairns, J.A. and Joyner, C. ( 1991) Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol 18: 349-355.
22. Connolly, S., Pogue, J., Hart, R., Pfeffer, M., Hohnloser, S., Chrolavicius, S. et al. (2006) ACTIVE Writing Group of the ACTIVE Investigators: Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial. Lancet 367: 1903-1912.
23. EAFT (European Atrial Fibrillation Trial) Study Group ( 1993) Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342: 1255-1262.
24. Eriksson, B.I., Quinlan, D.J. and Weitz, J.I. (2009) Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 48: 1-22.
25. Eriksson, B.I., Turpie, A.G., Lassen, M.R., Prins, M.H., Agnelli, G., Kälebo, P. et al. (2007) ONYX study group. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 5: 1660-1665.
26. Executive Steering Committee of the SPORTIF III Investigators (2003) Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial. Lancet 362: 1691-1698.
27. Ezekowitz, M.D., Bridgers, S.L., James, K.E., Carliner, N.H., Colling, C.L., Gornick, C.C. et al. (1992) Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Eng J Med 327: 1406-1412.
28. Ezekowitz, M.D., Reilly, P.A., Nehmiz, G., Simmers, T.A., Nagarakanti, R., Parcham-Azad, K. et al. (2007) Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 100: 1419-1426.
29. Fauler, J. ( 2009) Clinical pharmacology of antithrombotic drugs in coronary artery disease. Ther Adv Cardiovasc Dis 3: 465-478.
30. Flegel, K.M., Shipley, M.J. and Rose, G. ( 1987) Risk of stroke in non-rheumatic atrial fibrillation [published erratum in Lancet 1987; 1: 878]. Lancet 1: 526-529.
31. Fukuda, T., Matsumoto, C., Honda, Y., Sugiyama, N., Morishima, Y. and Shibano, T. ( 2004) Antithrombotic properties of DU-176b, a novel, potent and orally active direct factor Xa inhibitor in rat models of arterial and venous thrombosis: Comparison with fondaparinux, an antithrombin dependent factor Xa inhibitor. American Society of Hematology annual meeting. Blood 104, abstract 1852.
32. Furugohri, T., Honda, Y., Matsumoto, C., Isobe, K., Sugiyama, N., Morishima, Y. et al. (2004) Antithrombotic and hemorrhagic effects of DU-176b, a novel, potent and orally active direct factor Xa inhibitor: A wider safety margin compared to heparins and warfarin. American Society of Hematology annual meeting 2004 Blood 104, abstract 1851.
33. Gage, B.F. ( 2009) Can we rely on RE-LY? N Eng J Med 361: 1200-1202.
34. Giugliano, R.P., Wiviott, S.D., Stone, P.H., Simon, D.I., Schweiger, M.J., Bouchard, A. et al. (2007) Recombinant nematode anticoagulant protein c 2 in patients with non-ST-segment elevation acute coronary syndrome: The ANTHEM-TIMI-32 trial. J Am Coll Cardiol 49: 2398-2407.
35. Go, A.S., Hylek, E.M., Phillips, K.A., Chang, Y., Henault, L.E., Selby, J.V. et al. (2001) Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285: 2370-2375.
36. Gross, P.L. and Weitz, J.I. ( 2008) New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 28: 380-386.
37. Gruber, A., Marzec, U.M., Buetehorn, U., Hanson, S. and Perzborn, E. ( 2008) Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates. American Society of Hematology annual meeting 2008. Blood 112, abstract 3825.
38. Grutter, M.G., Priestle, J.P., Rahuel, J., Grossenbacher, H., Bode, W., Hofsteenge, J. et al. (1990) Crystal structure of the thrombin-hirudin complex: A novel mode of serine protease inhibition. EMBO J 9: 2361-2365.
39. Gulløv, A.L., Koefoed, B.G., Petersen, P., Pedersen, T.S., Andersen, E.D., Godtfredsen, J. et al. (1998) Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 158: 1513-1521.
40. Hart, R.G., Pearce, L.A. and Aguilar, M.I. ( 2007) Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146: 857-867.
41. Hellemons, B.S., Langenberg, M., Lodder, J., Vermeer, F., Schouten, H.J., Lemmens, T. et al. (1999) Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: Randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ 319: 958-964.
42. Hirsh, J., Dalen, J., Anderson, D.R., Poller, L., Bussey, H., Ansell, J. et al. (2001 a) Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimum therapeutic range. Chest 119(Suppl): 8S-21S.
43. Hirsh, J., Warkentin, T.E., Shaughnessy, S.G., Anand, S.S., Halperin, J.L., Raschke, R. et al. (2001 b) Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119(Suppl): 64S-94S.
44. Hirsh, J. and Weitz, J.I. ( 1999) New antithrombotic agents. Lancet 353: 1431-1436.
45. Iwatsuki, Y., Shigenaga, T., Moritani, Y., Suzuki, M., Ishihara, T., Hirayama, F. et al. (2006) Biochemical and pharmacological profiles of YM150, an oral direct factor Xa inhibitor. Blood 108, abstract 911.
46. Krahn, A.D., Manfreda, J., Tate, R.B., Mathewson, F.A. and Cuddy, T.E. ( 1995) The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 98: 476-484.
47. Kubitza, D., Becka, M., Wensing, G., Voith, B. and Zuehlsdorf, M. ( 2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61: 873-880.
48. Kubitza, D., Becka, M., Zuehlsdorf, M. and Mueck, W. ( 2006) Effect of food, an antacid, and the H 2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 46: 549-558.
49. Kubitza, D., Becka, M., Zuehlsdorf, M. and Mueck, W. ( 2007) Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 47: 218-226.
50. Lawson, J.H. and Mann, K.G. ( 1991) Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. J Biol Chem 266: 11317-11327.
51. Lee, A., Agnelli, G., Buller, H., Ginsberg, J., Heit, J., Rote, W. et al. (2001) Dose-response study of recombinant factor VIIa / tissue factor inhibitor recombinant nematode anticoagulant protein c 2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 104: 74-78.
52. Levy, S., Maarek, M., Coumel, P., Guize, L., Lekieffre, J., Medvedowsky, J.L. et al. for the College of French Cardiologists ( 1999) Characterization of different subsets of atrial fibrillation in general practice in France: The ALFA study. Circulation 99: 3028-3035.
53. Lu, G., de Guzman, F.R., Lakhotia, S., Hollenbach, S.J., Philips, D.R. and Sinha, U. ( 2008) Recombinant antidote for reversal of anticoagulation by factor Xa inhibitors. American Society of Hematology annual meeting. Blood 112, abstract 983.
54. Mant, J., Hobbs, F.D., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G.Y. et al. (2007) BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial. Lancet 370: 493-503.
55. McNamara, R.L., Tamariz, L.J., Segal, J.B. and Bass, E.B. ( 2003) Management of atrial fibrillation: Review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 139: 1018-1033.
56. Miyasaka, Y., Barnes, M.E., Gersh, B.J., Cha, S.S., Bailey, K.R., Abhayaratna, W.P. et al. (2006) Secular trends in incidence of atrial fibrillation in Olmstead County, Minnesota, 1980-2000, and implications on the projections for future prevalence. Circulation 114: 119-125.
57. Morocutti, C., Amabile, G., Fattapposta, F., Nicolosi, A., Matteoli, S., Trappolini, M. et al. (1997) Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke 28 (5): 1015-1021.
58. Mueck, W., Becka, M., Kubitza, D., Voith, B. and Zuehlsdorf, M. ( 2007) Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in healthy subjects. Int J Clin Pharmacol Therap 45: 335-344.
59. Mueller, R.L. and Scheidt, S. ( 1994) History of drugs for thrombotic disease. Discovery, development, and directions for the future. Circulation 89: 432-449.
60. Nutescu, E.A., Shapiro, N.L. and Chevalier, A. ( 2008) New anticoagulant agents: Direct thrombin inhibitors. Cardiol Clin 26: 169-187.
61. Olsson, S.B., Executive Steering Committee of the SPORTIF III Investigators (2003) Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial. Lancet 362: 1691-1698.
62. Pérez-Gómez, F., Alegría, E., Berjón, J., Iriarte, J.A., Zumalde, J., Salvador, A. et al. NASPEAF Investigators (2004 ) Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: A randomized multicenter study. J Am Coll Cardiol 44: 1557-1566.
63. Perzborn, E., Strassburger, J., Wilmein, A., Pohlmann, J., Roehrig, S., Schlemmer, K.H. et al. (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939: An oral, direct factor Xa inhibitor. J Thromb Haemost 3: 514-521.
64. Petersen, P. and Boysen, G. ( 1990) Stroke prevention in atrial fibrillation study. N Engl J Med 323: 482.
65. Petersen, P., Boysen, G., Godtfredsen, J., Andersen, E.D. and Andersen, B. ( 1989) Placebo controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1: 175-179.
66. Pinto, D.J., Orwat, M.J., Koch, S., Rossi, K.A., Alexander, R.S., Smallwood, A. et al. (2007) Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carb-oxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 50: 5339-5356.
67. Presta, L., Sims, P., Meng, Y.G., Moran, P., Bullens, S., Bunting, S. et al. (2001) Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic. Thromb Haemost 85: 379-389.
68. Psaty, B.M., Manolio, T.A., Kuller, L.H., Kronmal, R.A., Cushman, M., Fried, L.P. et al. (1997) Incidence of and risk factors for atrial fibrillation in older adults. Circulation 96 (7): 2455-2461.
69. Ragni, M., Cirillo, P., Pascucci, I., Scognamiglio, A., D'Andrea, D., Eramo, N. et al. (1996) Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis. Circulation 93: 1913-1918.
70. Rocket A.F. Study Investigators (2010) Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and design of the ROCKET AF study. Am Heart J 159: 340-347.e1.
71. Rothlein, R., Shen, J.M., Naser, N., Gohimukkula, D.R., Caligan, T.B., Andrews, R.C. et al. (2005) TTP889, a novel orally active partial inhibitor of FIXa inhibits clotting in two A / V shunt models without prolonging bleeding times. Blood 106, abstract 1886.
72. Rydel, T.J., Ravichandran, K.G., Tulinsky, A., Bode, W., Hubert, R., Roitsch, C. et al. (1990) The structure of a complex of recombinant hirudin and human alpha-thrombin. Science 249: 277-280.
73. Shapiro, S.S. ( 2003) Treating thrombosis in the 21st century. N Engl J Med 349: 1762-1764.
74. Sheeha, J.P. and Sadler, J.E. ( 1994) Molecular mapping of the heparin-binding exosite of thrombin. Proc Natl Acad Sci U S A 91: 5518-5522.
75. Shirk, R.A. and Vlasuk, G.P. ( 2007) Inhibitors of factor VIIa / tissue factor. Arterioscler Thromb Vasc Biol 27: 1895-1900.
76. Stassens, P., Bergum, P.W., Gansemans, Y., Jespers, L., Laroche, Y., Huang, S. et al. (1996) Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci U S A 93: 2149-2154.
77. Steffel, J., Lüscher, T.F. and Tanner, F.C. ( 2006) Tissue factor in cardiovascular disease. Molecular mechanisms and clinical implications. Circulation 113: 722-731.
78. Stroke Prevention in Atrial Fibrillation Study Group ( 1991) Final results. Circulation 84: 527-539.
79. Stroke Prevention in Atrial Fibrillation II Study Group ( 1994) Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 343: 687-691.
80. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators (1990) The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 323: 1505-1511.
81. Ufer, M. ( 2005) Comparative pharmacokinetics of vitamin K antagonists: Warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 44: 1227-1246.
82. van Walraven, C., Hart, R.G., Singer, D.E., Laupacis, A., Connolly, S., Petersen, P. et al. (2002) Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: An individual patient meta-analysis. JAMA 288: 2441-2448.
83. Wallentin, L., Ezekowitz, M., Simmers, T.A., Pedersen, K.A., Stangier, J., Nehmiz, G. et al. (2005) PETRO-investigators. Safety and efficacy of a new oral direct thrombin inhibitor dabigatran in atrial fibrillation: A dose finding trial with comparison to warfarin. Eur Heart J 26(Suppl): 403-617.
84. Weitz, J. and Hirsh, J. ( 2001) New anticoagulant drugs. Chest 119(Suppl): 95S-107S.
85. Weitz, J.I. and Buller, H.R. ( 2002) Direct thrombin inhibitors in acute coronary syndromes: Present and future. Circulation 105: 1004-1011.
86. Weitz, J.I., Connolly, S.T.J. and Kunitada, S. ( 2008) Randomized, parallel group, multicenter, multinational study evaluating safety of DU-176b compared with warfarin in subjects with nonvalvular atrial fibrillation. Blood 2008, abstract 33.
87. Weitz, J.I. and Crowther, M. ( 2002) Direct thrombin inhibitors. Thromb Res 106: V275-V284.
88. Wolf, P.A., Abbott, R.D. and Kannel, W.B. ( 1987) Atrial fibrillation: A major contributor to stroke in the elderly: The Framingham Study. Arch Intern Med 147: 1561-1564.
89. Wolf, P.A., Abbott, R.D. and Kannel, W.B. ( 1991) Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 22: 983-988.
90. Wolf, P.A., Dawber, T.R., Thomas Jr, H.E. and Kannel, W.B. ( 1978) Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham Study. Neurology 28: 973-977.
91. Writing ACTIVE Group (2006) Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial. Lancet 367: 1903-1912.
92. Zafar, M.U., Vorchheimer, D.A., Gaztanaga, J., Velez, M., Yadegar, D., Moreno, P.R. et al. (2007) Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 98 (4): 883-888.